Literature DB >> 6328984

Regulation of renal hemodynamics and glomerular filtration in patients with renovascular hypertension during converting enzyme inhibition with captopril.

S C Textor, R C Tarazi, A C Novick, E L Bravo, F M Fouad.   

Abstract

Changes in regional hemodynamics and function of the kidney during inhibition of angiotensin converting enzyme were studied in 25 patients with renovascular hypertension. A variety of patterns were observed depending upon (1) the activity of the renin-angiotensin system and concomitant administration of diuretics, and (2) the presence of bilateral renal artery stenosis. Increase in blood flow, glomerular filtration rate and sodium excretion during angiotensin blockade, in some instances, indicated tonic renal vasoconstriction before therapy. Release of the kidney from these effects may explain, in part, the sustained effectiveness of converting enzyme inhibition in chronic congestive heart failure. When compared with blood pressure reduction due to nitroprusside administration, initial captopril therapy in patients with unilateral stenosis produced a selective decrease in glomerular filtration, despite well-preserved renal blood flow. These results confirm the importance of efferent arteriolar vasoconstriction due to angiotensin II in man. Experimental studies demonstrate that angiotensin may become critical to sustaining glomerular filtration rate in the presence of stenosis during vasodilation. In patients with bilateral stenosis, this effect produces a syndrome of functional renal insufficiency. Taken together, these data demonstrate an intrarenal action of angiotensin II in human renovascular hypertension and underscore the importance of evaluating the functional impact of changes in regional hemodynamics.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6328984     DOI: 10.1016/0002-9343(84)90880-5

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  11 in total

Review 1.  Atherosclerotic renovascular disease.

Authors:  Sheldon W Tobe; Ellen Burgess; Marcel Lebel
Journal:  Can J Cardiol       Date:  2006-05-15       Impact factor: 5.223

Review 2.  ACE inhibitors in renovascular hypertension.

Authors:  S C Textor
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

Review 3.  ACE inhibitors and the kidney. A risk-benefit assessment.

Authors:  G Navis; H J Faber; D de Zeeuw; P E de Jong
Journal:  Drug Saf       Date:  1996-09       Impact factor: 5.606

Review 4.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

Review 5.  Adverse reactions with angiotensin converting enzyme (ACE) inhibitors.

Authors:  R DiBianco
Journal:  Med Toxicol       Date:  1986 Mar-Apr

6.  Comparison of 1.5 and 3 T BOLD MR to study oxygenation of kidney cortex and medulla in human renovascular disease.

Authors:  Monika L Gloviczki; James Glockner; Sabas I Gomez; Juan C Romero; Lilach O Lerman; Michael McKusick; Stephen C Textor
Journal:  Invest Radiol       Date:  2009-09       Impact factor: 6.016

Review 7.  Ramipril. A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders.

Authors:  P A Todd; P Benfield
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

Review 8.  Drug therapy of renovascular hypertension.

Authors:  Talma Rosenthal
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 9.  Blockade of the renin-angiotensin system in hypertensive patients with atherosclerotic renal artery stenosis.

Authors:  Faical Jarraya; Menno Pruijm; Gregoire Wuerzner; Michel Burnier
Journal:  Curr Hypertens Rep       Date:  2013-10       Impact factor: 5.369

10.  Enalapril versus triple-drug therapy in the treatment of renovascular hypertension.

Authors:  G P Reams; J H Bauer
Journal:  Drugs       Date:  1985       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.